StockData

GSK vs Regeneron Pharmaceuticals

GSK and REGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GSK and REGN compare

Regeneron Pharmaceuticals grew revenue faster over the last twelve months (18.6% versus 4.1% for GSK).

Regeneron Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 28.5% compared with 17.5% at GSK.

Regeneron Pharmaceuticals pays a dividend yielding 0.39%; GSK does not pay one.

Regeneron Pharmaceuticals scores higher on the StockData Score (16 against 9 for GSK), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGSKREGN
Size and price
Market cap–$98.5B
Share price$50.41$952.40
Change, 1 year4.7%37.0%
Change, 5 years0.24%48.0%
Beta (5Y)0.090.16
Employees500K15K
StockData Score
Total score916 (better)
Valuation score01 (better)
Growth score22
Performance score44
Health score36 (better)
Dividend score03 (better)
Valuation
P/E–21.0×
P/S–5.8×
P/B–2.9×
EV/EBITDA–17.0×
P/FCF–25.7×
PEG–7.61
FCF yield–3.9%
Fair value–$862.07
Margin of safety–−10.5%
Growth
Revenue growth (TTM)4.1%18.6% (better)
Revenue growth, 5Y average6.0%11.0% (better)
Net income growth (TTM)122% (better)5.2%
EPS growth (TTM)123% (better)8.4%
EPS growth, 5Y average−0.54%6.3% (better)
Profitability
Gross margin72.4%–
Operating margin24.3%28.8% (better)
Net margin17.5%28.5% (better)
FCF margin19.6%22.6% (better)
Return on equity38.0% (better)14.9%
Return on invested capital23.4% (better)16.3%
Financial health
Debt / equity1.080.06 (better)
Net debt / EBITDA1.40 (better)−1.36
Interest coverage11.3×104× (better)
Current ratio0.823.35 (better)
Altman Z-score–7.80
Piotroski F-score9 (better)5
Dividends and buybacks
Dividend yield–0.39%
Payout ratio44.9%8.0%
Buyback yield–2.0%
Shareholder yield–2.4%
Ownership
Held by institutions8.0%88.5%
Held by insiders0.00%3.7%
Insider net buying, 12 months–−$57.4M
Superinvestors holding11
Short interest, % of float–2.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.